TOTAL: $60.7M
Year to Date: $999.35M
Company (Symbol)#* Partner

(Country)

 Amt.

(M)

 Triggering

Event

 Details (Date)
Bavarian Nordic A/S (Denmark; CSE:BAVA) Department of Health and Human Services $25 Milestone payment The payment is being awarded as part of a contract to manufacture and deliver 20M doses of Imvamune smallpox vaccine (11/29)
Emergent BioSolutions Inc. (NYSE:EBS) Department of Health and Human Services $8.8 Milestone payment For the completion of a human study to support the expansion of BioThrax in post-exposure prophylaxis in people exposed to anthrax (11/5)
Epix Pharmaceuticals Inc. (EPIX) GlaxoSmithKline plc (UK) $3 Milestone payment Epix achieved the milestone related to the second of three discovery programs; it identified three lead candidates in a second G-protein coupled receptor discovery program (11/6)
Exelixis Inc. (EXEL) Bristol-Myers Squibb Co. $5 Milestone payment For the acceptance of an investigational new drug application or foreign equivalent for a compound discovered and developed under the firms' liver X receptor collaboration (11/29)
Gene Logic Inc. (GLGC) Pfizer Inc. ND Milestone payment Gene Logic received the payment for work on a patent application; it is working to find new therapeutic applications for drug candidates no longer in active development (11/20)
Pharmacopeia (PCOP) GlaxoSmithKline plc(UK) $1 Milestone payment Pharmacopeia received the payment for the identification of two lead compounds to treat respiratory disease and inflammatory pain (11/27)
Rigel Pharmaceuticals Inc. (RIGL) Merck Serono SA (Germany) $3 Milestone payment For Merck Serono's exercise of an option to pick up Japanese rights to Rigel's Aurora kinase inhibitors (11/14)
Vectura Group plc (UK; LSE:VEC) Boehringer Ingelheim (Germany) €10 ($14.9) Milestone payment The payment is related to a collaboration on the development of a multidose dry powder inhaler for use in the treatment of respiratory diseases; Boeheringer also is making an equity investment in Vectura of €5M for 3.6M shares (11/28**)
Viropro International Inc. (unit of Viropro Inc.; Canada; OTC BB:VPRO) Intas Biopharma-ceuticals Ltd. (India) ND Milestone payment Viropro received the payment as part of its contract related to the development and production of an undisclosed therapeutic protein (11/29)
Notes:
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.* Private company. Currency conversions are based on exchange rates at the time of the deal. ND = Not disclosed. CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.